<DOC>
	<DOCNO>NCT00208169</DOCNO>
	<brief_summary>It hypothesize use aripiprazole ( Abilify ) patient alcohol and/or drug dependence comorbid psychiatric condition lead : - Reduction amount alcohol and/or drug use measured Time Line Follow Back ( TLFB ) Addiction Severity Index ( ASI ) - Reduction craving alcohol drug measure Penn Alcohol Craving Scale - Reduction symptom co-morbid psychiatric disorder compare start aripiprazole .</brief_summary>
	<brief_title>Abilify Therapy Reducing Comorbid Substance Abuse</brief_title>
	<detailed_description>Substance abuse disorder major public health problem . With current prevalence rate 18 % , substance abuse dependence cost nation $ 300 billion per year treatment cost lose productivity . Approximately 20 % patient attend primary care clinic 35 % patient attend psychiatric clinic meet Diagnostic Statistical Manual IV ( DSM IV ) criterion substance abuse dependence . The treatment substance abuse dependence disorder complex involves individual group therapy , maintenance sobriety , commitment structure living , participation self-help group . To date , pharmacotherapy substance dependence disorder limit success . Several medication test past , include tricyclic antidepressant , selective serotonin reuptake inhibitor , buspirone , bupropion , venlafaxine , nefazodone , bromocriptine , amantadine , naltrexone , acamprosate . Of , naltrexone obtain FDA indication treatment alcohol dependence , acamprosate use Europe . However , medication effective relatively small proportion patient . Benzodiazepines may useful treatment withdrawal syndrome , potential abuse dependence limit use maintenance treatment . This open label pilot study aripiprazole therapy treatment patient substance use disorder co-morbid disorder like Schizophrenia , Schizoaffective disorder , Bipolar disorder , Major depressive disorder , Anxiety ( Panic disorder , Generalized Anxiety Disorder , Post-Traumatic Stress Disorder ) . While Aripiprazole approve treatment Schizophrenia , use psychiatric disorder label use . Increasing evidence suggest Aripiprazole might offer benefit psychiatric disorder besides Schizophrenia .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1 . Ages 19 65 2 . Diagnosis schizophrenia , schizoaffective disorder , bipolar disorder , major depressive disorder , anxiety ( panic disorder , generalize anxiety disorder , posttraumatic stress disorder ) confirm Mini International Neuropsychiatric Interview ( MINI ) structure assessment 3 . Diagnosis comorbid substance abuse/dependence confirm MINI structure assessment 4 . Ability provide sign informed consent 5 . Stable general medical health 6 . Ability attend outpatient research clinic . 1 . Dangerous self others 2 . Pregnancy , inability unwillingness use approve method birth control 3 . Inability unwillingness provide sign informed consent 4 . Inability attend outpatient research clinic 5 . Medical condition , would preclude use aripiprazole 6 . Absolute need ongoing treatment antipsychotic aripiprazole 7 . Medical instability define likelihood needing change prescription medication course study 8 . Patients prior unsuccessful treatment aripiprazole 9 . Patients psychiatric diagnosis antisocial personality disorder eat disorder comorbid substance abuse/dependence .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Comorbid substance abuse/dependence</keyword>
	<keyword>Comorbid diagnosis</keyword>
	<keyword>Substance abuse and/or dependence</keyword>
</DOC>